Gilead Sciences (GILD) Tops Q2 EPS by 5c, Beats on Revenue; Offers FY25 Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/6/2026
- S&P 500, Nasdaq close sharply higher as Broadcom rallies
- Oil prices settle at pre-Iran war levels as crude output grows
- Broadcom stock pops 4% as Apple silicon deal gets extended through 2031
- Buy the pullback in chip stocks, JPM's Matejka says
- Memory stocks rebound as analysts flag a buying opportunity
- Rivian Automotive (RIVN) files for 75M share offering
- Rivian offers Q2 2026 revenue outlook, cash position grows
- Nokia OYJ (NOKIA:FH) (NOK) PT Raised to EUR14 at Kepler Cheuvreux
- Meta capex to surge in 2027, neocloud fears ’erroneous’ - SemiAnalysis
- Broadcom secures role as key Apple supplier with chip deal through 2031
Gilead Sciences Announces Second Quarter 2025 Financial Results
August 7, 2025 4:22 PM EDTProduct Sales Excluding Veklury Increased 4% Year-Over-Year to $6.9 billion
Biktarvy Sales Increased 9% Year-Over-Year to $3.5 billion
FOSTER CITY, Calif.--(BUSINESS WIRE)-- Gilead Sciences, Inc. (Nasdaq: GILD) announced today its second quarter 2025 results of operations.
This was a very successful second quarter for Gilead, including the FDA approval for Yeztugo as the worlds first twice-yearly HIV prevention option, said Daniel ODay, Gileads Chairman and Chief Executive Officer. Our strong growth this quarter was driven by Biktarvy, Descovy, Trodelvy and Livdelzi, reflecting the... More
